In a @-week , phase @ , dose-ranging , randomized , double-blind , placebo-controlled , active-comparator trial , we compared guselkumab ( CNTO @ ) , an anti-interleukin-@ monoclonal antibody , with adalimumab in patients with moderate-to-severe plaque psoriasis .